Moreover, a new orally active compound, SEP-363856 (Ulotaront, TAAR1 agonist with 5-HT1A receptor activity), has been tested in recent clinical trials as a psychotropic agent for the treatment of psychosis in schizophrenia [28]. Here, HTR1A is linked to psychotic disorder.